Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis

Gastrointestinal cytomegalovirus (CMV) disease in ANCA-associated vasculitis is associated with significant morbidity. Studies should be performed to identify the epidemiology and risk factors for CMV disease in AAV so that vulnerable patients may be risk-stratified for consideration of preventive s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2018-07, Vol.37 (7), p.2011-2012
Main Authors: Lim, Cynthia C., Mok, Irene Y. J., Choo, Jason C. J.
Format: Article
Language:English
Subjects:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy
Antineutrophil cytoplasmic antibodies
Antiviral agents
Antiviral Agents - therapeutic use
Cost-Benefit Analysis
Cytomegalovirus
Cytomegalovirus Infections - etiology
Cytomegalovirus Infections - prevention & control
Disease prevention
Humans
Immunocompromised Host
Immunosuppressive agents
Immunosuppressive Agents - therapeutic use
Letter to the Editor
Medicine
Medicine & Public Health
Morbidity
Mortality
Prophylaxis
Rheumatology
Risk factors
Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal cytomegalovirus (CMV) disease in ANCA-associated vasculitis is associated with significant morbidity. Studies should be performed to identify the epidemiology and risk factors for CMV disease in AAV so that vulnerable patients may be risk-stratified for consideration of preventive strategies such as surveillance and pre-emptive therapy or anti-viral prophylaxis. Given the absence of evidence-based guidelines for prevention of CMV disease in patients with AAV receiving potent immunosuppressive therapy, further risk-benefit studies are required to ascertain if preventive strategies will reduce CMV-related morbidity and mortality in individuals with AAV.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-018-4101-7